Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027

Published: Dec 2022 Pages: 162 SKU: IRTNTR70733

Chronic Obstructive Pulmonary Disease Drugs Market Size 2023-2027

The chronic obstructive pulmonary disease drugs market is estimated to grow by USD 6.65 billion at a CAGR of 6.09% between 2022 and 2027. Market growth depends on several factors, including the increasing incidence of chronic obstructive pulmonary disease, a robust pipeline of new drugs receiving approvals, and rising demand for fixed-dose combinations. The prevalence of COPD, a chronic inflammatory lung disease, is on the rise globally, driving the need for effective treatments. The pharmaceutical industry's focus on developing novel drugs and receiving regulatory approvals is fueling market expansion. Additionally, the demand for fixed-dose combinations, which offer convenience and improved adherence, is growing. These factors collectively contribute to the market's growth trajectory, indicating a promising future for COPD therapeutics as they cater to the evolving needs of patients and healthcare providers.

It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation

This market report extensively covers market segmentation by product (combination therapy and monotherapy), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

By Product

The market share growth by the combination therapy segment will be significant during the forecast period. Combination therapy involves the use of two or more therapeutic agents for the treatment of a disease. Most of the leading manufacturers in the market have developed a single-dose form by combining 2-3 different types of drug classes for effective treatment. Moreover, combination therapy drugs are novel in the sense that they have multiple pharmacologic effects on the body. During the last decade, various high-efficacy combinations of novel bronchodilators have been approved for the treatment. Such factors will increase segment growth during the forecast period.

Get a glance at the market contribution of various segments View PDF Sample

The combination therapy segment was valued at USD 10.78 billion in 2017. The pipeline is flooded with combination therapy drugs, most of which are in the registration and pre-registration phases of development. For instance, in December 2020, AstraZeneca's Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) was approved in the European Union (EU) for maintenance treatment in adult patients with moderate-to-severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA). This is the fourth major approval for AstraZeneca's triple-combination therapy, which is marketed as Breztri Aerosphere in the US, China, and Japan. Thus, late-stage pipeline molecules and recent product approval will contribute to the growth of the segment during the forecast period.

By Region

For more insights on the market share of various regions View PDF Sample now!

North America is estimated to contribute 50% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Market growth in North America can be attributed to three major drivers, namely, the growing incidence of COPD, the availability of reimbursement schemes, and approvals for new triple combination drugs for the treatment of COPD. The rising incidence of COPD is a major driving factor for the market in North America.  As per the National Institutes of Health (NIH), COPD is one of the leading causes of death in the US, and in 2020, it affected 16 million people in the US. Risk factors for COPD, such as smoking and air pollutants, have also been increasing drastically over the past three decades. These factors will facilitate market growth during the forecast period.

Market Dynamics and Customer Landscape

The market is influenced by organizations like the World Health Organisation (WHO) and the Centre for Disease Control and Prevention (CDCP), which highlight the disease burden of COPD. The Global Burden of Disease Study and the Institute of Health Metrics and Evaluation provide insights into its impact on global health. Factors such as tobacco consumption, especially among the youth population, contribute to its prevalence. Expenditure on healthcare is significant, particularly in developing and underdeveloped countries. R&D investment is crucial for developing innovative therapies and treatment approaches to manage COPD and improve outcomes and quality of life. These efforts focus on diagnosis, recognition, and the development of diagnostic tools and treatments for COPD, including generic drugs. Addressing smoking tobacco and reducing workplace and indoor air pollution are key strategies for its management. Patients require long-term care and specialized treatment to manage COPD effectively. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The increasing prevalence of COPD is accelerating the growth of the market globally. This is a chronic non-communicable lifestyle-related disease that progresses steadily without medical intervention. There are several lifestyle-related factors, such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. Because of the significant prevalence of these factors in the environment worldwide, COPD has become a leading cause of mortality and morbidity globally. As per Natalie Terzikhan et al., COPD is considered the third-leading cause of death worldwide. Smoking is considered the leading cause of COPD, especially in developed countries where cigarette smoking is widespread.

Tobacco smoke from pipes, cigars, and cigarettes is indeed an irritant that affects the bronchi and the alveoli of the lungs, leading to chronic obstructive pulmonary disease (COPD). Smoking tobacco is a major risk factor for developing COPD, and understanding its effects is crucial for diagnosis and treatment approaches. The symptoms usually appear after 40 years of age. Hence, the growth of the global geriatric population will further increase the number of people at risk. Likewise, rare genetic conditions such as alpha-1 antitrypsin deficiency predispose people to an increased risk. Since alpha-1 antitrypsin is a protein that helps to protect the lungs from damage caused by inflammation, people who do not have this protein are more susceptible to COPD.

Significant Market Trends

Expanding research in curative approaches is the key market trend driving market growth. Considerable research is underway to find the ideal treatment. Researchers identify molecular targets that drive this disease progression. The identification of molecular targets is necessary for the development of new biological therapies, such as monoclonal antibodies, which can target physiological proteins responsible for disease progression.

Although some monoclonal antibodies failed to comply with the regulatory guidelines initially, there are other similar products in the pipeline for COPD. Similarly, some dual and triple-fixed-dose combination drugs are also in the late stages of development, owing to the multiple therapeutic benefits they provide. Apart from fixed-dose combination drugs that have entered the market or are in the registration phase, there are novel small molecular approaches that hold promising potential for the treatment of COPD.

Major Market Challenge

The high cost of COPD clinical trials is a major challenge hindering the growth of the market. The high cost of clinical trials for respiratory diseases is a major challenge for the market. The incidence has increased rapidly in recent years. According to ClinicalTrials.gov, there are few ongoing clinical trials for respiratory diseases. About 39 studies have been done on COPD. The costs associated with each stage of a clinical trial limit the number of studies that can be conducted in clinical trials.

Approximately USD115.3 million is spent for each phase of a clinical trial, which includes Phases I, II, III, and IV. Respiratory system studies ranked third in terms of cost spent per study in clinical trials. Therefore, the high cost of conducting clinical trials in respiratory disorders will negatively impact the growth of the global COPD drugs market during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AstraZeneca - The company offers chronic obstructive pulmonary disease drugs such as Pulmicort Turbuhaler. Also, the company engages in the discovery, development, manufacturing, marketing, and sale of pharmaceutical products.

The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

  • Exela Pharma Sciences LLC
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Innoviva Inc.
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Mundipharma International Ltd.
  • Novartis AG
  • Theravance Biopharma Inc.
  • Vertex Pharmaceuticals Inc.
  • Viatris Inc.
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Ltd.
  • CHIESI Farmaceutici SpA
  • Cipla Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024 to 2028, as well as historical data from 2018 to 2023 for the following segments.  

  • Product Outlook 
    • Combination therapy
    • Monotherapy
  • Distribution Channel Outlook
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
  • Region Outlook 
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Argentina
      • Austarlia
      • Rest of the world

Market Analyst Overview

The market is influenced by regulatory bodies like the FDA and the availability of generic drugs that can reduce healthcare costs in both developing countries and developed ones. Governments play a crucial role in promoting medical knowledge about COPD and reducing workplace pollution to prevent this chronic disease. COPD is often associated with comorbidities, and improving access to treatment is essential to prevent underdiagnoses and under treatment, ultimately improving patient outcomes.

Furthermore, COPD includes conditions like Chronic bronchitis and Emphysema, affecting the bronchial tubes and often exacerbated by asthma. Risk factors include exposure to chemicals and fumes from burning fuel, with a genetic factor such as alpha-1-antitrypsin deficiency also playing a role. Lifestyle changes like reducing drinking can help manage COPD, especially in developing countries where awareness and government investment in healthcare are crucial. The Pharmaceutical industry's investment in COPD treatments, including biosimilars after patent expiry, can also impact the market.

Market Scope

Report Coverage

Details

Page number

162

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 6.09%

Market growth 2023-2027

USD 6.65 billion

Market structure

Concentrated

YoY growth 2022-2023(%)

5.19

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 50%

Key countries

US, Canada, UK, Germany, and Japan

Competitive landscape

 Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks

Key companies profiled

AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Ltd., Philip Morris International Inc., Shionogi and Co. Ltd., Sumitomo Pharma Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Market dynamics

Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for market forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Get access to Report Sample PDF !

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global chronic obstructive pulmonary disease drugs market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global chronic obstructive pulmonary disease drugs market 2017 - 2021 ($ million)
    • 4.2 Product Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)
    • 4.3 Distribution channel Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Product

    • 6.1 Market segments
      • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
    • 6.2 Comparison by Product
      • Exhibit 32: Chart on Comparison by Product
      • Exhibit 33: Data Table on Comparison by Product
    • 6.3 Combination therapy - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
    • 6.4 Monotherapy - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
    • 6.5 Market opportunity by Product
      • Exhibit 42: Market opportunity by Product ($ million)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 45: Chart on Comparison by Distribution Channel
      • Exhibit 46: Data Table on Comparison by Distribution Channel
    • 7.3 Hospital pharmacies - Market size and forecast 2022-2027
      • Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.4 Retail pharmacies - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.5 Online pharmacies - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.6 Market opportunity by Distribution Channel
      • Exhibit 59: Market opportunity by Distribution Channel ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 61: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 62: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 63: Chart on Geographic comparison
      • Exhibit 64: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 Canada - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.10 Germany - Market size and forecast 2022-2027
      • Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.11 Japan - Market size and forecast 2022-2027
      • Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 101: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 102: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 104: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 105: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 106: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 107: Matrix on vendor position and classification
            • 12.3 AstraZeneca Plc
              • Exhibit 108: AstraZeneca Plc - Overview
              • Exhibit 109: AstraZeneca Plc - Product / Service
              • Exhibit 110: AstraZeneca Plc - Key news
              • Exhibit 111: AstraZeneca Plc - Key offerings
            • 12.4 Boehringer Ingelheim International GmbH
              • Exhibit 112: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 113: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 114: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 115: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 116: Boehringer Ingelheim International GmbH - Segment focus
            • 12.5 Cadila Pharmaceuticals Ltd.
              • Exhibit 117: Cadila Pharmaceuticals Ltd. - Overview
              • Exhibit 118: Cadila Pharmaceuticals Ltd. - Product / Service
              • Exhibit 119: Cadila Pharmaceuticals Ltd. - Key offerings
            • 12.6 Cipla Ltd.
              • Exhibit 120: Cipla Ltd. - Overview
              • Exhibit 121: Cipla Ltd. - Business segments
              • Exhibit 122: Cipla Ltd. - Key news
              • Exhibit 123: Cipla Ltd. - Key offerings
              • Exhibit 124: Cipla Ltd. - Segment focus
            • 12.7 Exela Pharma Sciences LLC
              • Exhibit 125: Exela Pharma Sciences LLC - Overview
              • Exhibit 126: Exela Pharma Sciences LLC - Product / Service
              • Exhibit 127: Exela Pharma Sciences LLC - Key offerings
            • 12.8 GlaxoSmithKline Plc
              • Exhibit 128: GlaxoSmithKline Plc - Overview
              • Exhibit 129: GlaxoSmithKline Plc - Business segments
              • Exhibit 130: GlaxoSmithKline Plc - Key offerings
              • Exhibit 131: GlaxoSmithKline Plc - Segment focus
            • 12.9 Lupin Ltd.
              • Exhibit 132: Lupin Ltd. - Overview
              • Exhibit 133: Lupin Ltd. - Product / Service
              • Exhibit 134: Lupin Ltd. - Key news
              • Exhibit 135: Lupin Ltd. - Key offerings
            • 12.10 Merck and Co. Inc.
              • Exhibit 136: Merck and Co. Inc. - Overview
              • Exhibit 137: Merck and Co. Inc. - Business segments
              • Exhibit 138: Merck and Co. Inc. - Key news
              • Exhibit 139: Merck and Co. Inc. - Key offerings
              • Exhibit 140: Merck and Co. Inc. - Segment focus
            • 12.11 Mundipharma International Ltd.
              • Exhibit 141: Mundipharma International Ltd. - Overview
              • Exhibit 142: Mundipharma International Ltd. - Product / Service
              • Exhibit 143: Mundipharma International Ltd. - Key offerings
            • 12.12 Novartis AG
              • Exhibit 144: Novartis AG - Overview
              • Exhibit 145: Novartis AG - Business segments
              • Exhibit 146: Novartis AG - Key offerings
              • Exhibit 147: Novartis AG - Segment focus
            • 12.13 Shionogi and Co. Ltd.
              • Exhibit 148: Shionogi and Co. Ltd. - Overview
              • Exhibit 149: Shionogi and Co. Ltd. - Product / Service
              • Exhibit 150: Shionogi and Co. Ltd. - Key offerings
            • 12.14 Sumitomo Pharma Co. Ltd.
              • Exhibit 151: Sumitomo Pharma Co. Ltd. - Overview
              • Exhibit 152: Sumitomo Pharma Co. Ltd. - Business segments
              • Exhibit 153: Sumitomo Pharma Co. Ltd. - Key offerings
              • Exhibit 154: Sumitomo Pharma Co. Ltd. - Segment focus
            • 12.15 Teva Pharmaceutical Industries Ltd.
              • Exhibit 155: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 156: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 157: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 159: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.16 Theravance Biopharma Inc.
              • Exhibit 160: Theravance Biopharma Inc. - Overview
              • Exhibit 161: Theravance Biopharma Inc. - Product / Service
              • Exhibit 162: Theravance Biopharma Inc. - Key offerings
            • 12.17 Viatris Inc.
              • Exhibit 163: Viatris Inc. - Overview
              • Exhibit 164: Viatris Inc. - Business segments
              • Exhibit 165: Viatris Inc. - Key offerings
              • Exhibit 166: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 167: Inclusions checklist
                • Exhibit 168: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 169: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 170: Research methodology
                • Exhibit 171: Validation techniques employed for market sizing
                • Exhibit 172: Information sources
              • 13.5 List of abbreviations
                • Exhibit 173: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              chronic obstructive pulmonary disease drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis